Management of Osteogenesis Imperfecta

Area of Science:

• Genetics and Molecular Biology
• Orthopedics
• Rheumatology

Background:

• Osteogenesis imperfecta (OI) is a group of rare inherited skeletal disorders characterized by a high risk of fragility fractures.
• Mutations in genes like COL1A1 and COL1A2 are common causes, leading to abnormal collagen production and reduced bone quality.
• While low bone mineral density (BMD) is a factor, bone quality defects are primary drivers of fragility in OI.

Purpose of the Study:

• To review the current understanding of Osteogenesis Imperfecta (OI) pathogenesis and treatment efficacy.
• To highlight the limitations of existing therapies in reducing fracture risk despite improvements in BMD.
• To emphasize the need for well-designed clinical trials with fracture endpoints for novel OI therapeutics.

Main Methods:

• Literature review of Osteogenesis Imperfecta (OI) pathogenesis and treatment modalities.
• Analysis of the efficacy of bisphosphonates, bone anabolic drugs (teriparatide, sclerostin inhibitors), denosumab, and cell therapy.
• Evaluation of the current evidence regarding fracture risk reduction and BMD changes.

Main Results:

• Bisphosphonates increase BMD in OI, but their effectiveness in reducing fracture risk is uncertain.
• Newer agents like teriparatide and sclerostin inhibitors show promise in increasing BMD but lack fracture endpoint data.
• Despite advances in understanding OI pathogenesis, effective treatments for reducing fracture risk remain limited.

Conclusions:

• A multidisciplinary approach is crucial for managing OI, involving various healthcare professionals.
• Existing treatments for OI primarily focus on increasing BMD, with limited evidence on fracture risk reduction.
• There is an urgent need for robust clinical trials evaluating new and existing therapies for OI, focusing on fracture endpoints.